Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.59 |
| ▸ | AURKA | O14965 | 8/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15197035 | 1.00 | AKT1 (0.66) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL529302 | 1.00 | AKT1 (0.66) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL18597232 | 1.00 | AKT1 (0.66) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL527654 | 0.92 | AKT1 (0.78) | AKT1RPS6KB1AURKAAURKB | |
| SCHEMBL528494 | 0.92 | AKT1 (0.78) | AKT1RPS6KB1AURKAAURKB | |
| SCHEMBL15197055 | 0.92 | AKT1 (0.78) | AKT1RPS6KB1AURKAAURKB | |
| SCHEMBL530474 | 0.91 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL527695 | 0.91 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL15197025 | 0.91 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKAAURKBINCENP | |
| SCHEMBL528234 | 0.91 | RPS6KB1 (0.72) | AKT1RPS6KB1AURKAAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | claimed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | claimed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | claimed |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | AKT1 1178/4885RPS6KB1 1117/4885AURKA 301/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | AKT1 1178/4885RPS6KB1 1117/4885AURKA 301/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | AKT1 1178/4885RPS6KB1 1117/4885AURKA 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.